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Objective. To characterize the pediatric endocrinologists’ evaluation and followup of short-statured patients. Study Design.
Observational study of 21,548 short-statured children (April 1996 to December 1999). Baseline demographics, laboratory testing,
height standard deviation score (SDS), target height, and height relative to target height were analyzed at initial and return visits
with the specialist. Patients were scheduled for at least one return visit and no recombinant human growth hormone therapy was
administered. Results. Mean patient age was 8.6 years with a mean height SDS of −2.1. Patients were predominantly male (69%),
prepubertal (73%), and white (76%). Few screening tests were obtained during initial evaluation. Nearly 40% of children did not
return for their second scheduled visit. The follow-up rate was unrelated to demographics or degree of short stature. Conclusions.
Low return rates limit specialists’ ability to monitor growth or obtain laboratory testing over time. Further studies are needed
to determine which tests should be obtained at the initial clinic visit as well as the basis for the low return rate in this group of
children.
1.Introduction
Growth can be used as a proxy for a child’s health,
nutrition, and psychosocial well being. In the United States,
approximately2.2millionchildrenunder18yearsofagehave
heights below the third percentile [1]. Most will be healthy,
but a minority will have a pathologic etiology for their
short stature. Among the short-statured children who are
referred to a pediatric endocrinologist for the evaluation of
growth failure, only a minority are treated with recombinant
human growth hormone (rhGH). The clinical characteristics
of those who are evaluated for growth failure but do not
receive rhGH treatment are unknown.
When ﬁrst seeing a short-statured referral, the pediatric
endocrinologist must determine which patient requires
prompt extensive evaluation versus more conservative mon-
itoring. This decision is based on a combination of history,
genetic growth potential, prior laboratory testing, and
the degree of growth failure observed. Unfortunately, the
available growth records at the time of referral can often be
incomplete [2]. Forward monitoring of the child’s untreated
growth rate could be a valuable part of the evaluation.
However, the percentage of children who return for such
monitoring and the extent of laboratory screening eventually
performed are unknown.
The diagnostic and therapeutic approach to a patient
with short stature may diﬀer among pediatric endocrinol-
ogists. In 1995, a written survey was distributed to pediatric
endocrinologists in an attempt to determine the degree of
variability in the evaluation of the short child [3]. The survey
asked the 251 respondents (413 surveys distributed; 61%
response rate) to identify which screening tests were most
commonly used to aid in the diagnosis of growth failure and
to obtain feedback about recommendations for follow-up2 International Journal of Pediatric Endocrinology
care. The survey found that the majority of endocrinologists
stated that they were using a similar approach, especially in
regards to laboratory assessment. However, it is not known
whether this consensus would be seen with a more direct
monitoring of actual clinical practice.
The goal of this study was to characterize the initial diag-
nostic assessment and follow-up of untreated short-statured
subjects referred to pediatric endocrinologists. These results
werethencomparedwiththeﬁndingsofthephysiciansurvey
from 1995. Substudy 8 was speciﬁcally designed within
the National Cooperative Growth Study (NCGS) to collect
enrollment demographics as well as clinical and laboratory
data from patients referred to pediatric endocrinologists for
growth failure but not treated with rhGH. A preliminary
overview of the NCGS Substudy 8 data was previously
described[4].Thedetailedanalysisispresentedinthispaper.
2.PatientSelectionandMethods
The NCGS is an ongoing postmarketing surveillance study
of children receiving Genentech rhGH. Approximately 400
institutions from across the United States contribute to
this long-running registry. The NCGS Substudy 8 was a
prospective, observational study designed to characterize
the enrollment demographics of subjects referred to NCGS
investigators for evaluation of growth failure and to delineate
the assessment process and diagnostic procedures used.
Participating centers were invited to enroll patients in
Substudy8fromApril1996toDecember1999.Thesubstudy
was closed to further data collection in December 2001.
Data were collected from pediatric endocrinologists as they
examined short or poorly growing children referred by their
primary health care provider. After the initial evaluation
for short stature, investigators were instructed to enroll
all consenting patients who had signiﬁcant growth failure
worthy of monitoring over more than one follow-up visit.
Patients without signiﬁcant growth failure who did not
require follow-up visits were excluded from the study. Each
participating pediatric endocrinologist subjectively deﬁned
signiﬁcant growth failure. Patients did not receive rhGH
beforeorduringtheobservationperiod.IfrhGHtherapywas
initiated during observation, the patient was excluded. All
patients enrolled in Substudy 8 whose age at referral was 20
years or younger and whose height standard deviation score
(SDS) could be calculated were included in these analyses.
Where appropriate, institutional review board approval and
informed consent for transmission of anonymized data were
obtained.
Baseline data including sex, race/ethnic origin, birth
weightandlength,biologicalparents’heights,ageatpubertal
onset, referral source, and medical history were collected.
At baseline and subsequent visits, investigators recorded
the date of the visit, height, weight, Tanner stage, current
medications, radiologic tests obtained (including bone age
andcentralnervoussystemimaging),laboratoryassessments
(including evaluation of the growth hormone-insulin-like
growth factor [GH-IGF] axis), presumed etiology of short
stature (if known), and treatment plan.
To estimate a child’s target height, his/her gender, the
parents’ heights, and a regression-to-the-mean factor of 0.8
described by Tanner [5] were used, where the adjusted target
height formulae are as follows.
Male adjusted target height is given as (cm) =
176.85cm+0.8×[(mother’s height (cm)+father’s height
(cm))/2+6.75−176.85].
Female adjusted target height is given as (cm) =
163.34cm +0.8×[(mother’s height (cm)+father’s height
(cm))/2−6.75−163.34].
With this regression-to-the-mean factor, a patient with
tall parents would have an adjusted target height lower
than predicted with the traditional midparental height
formula. Conversely, a patient with short parents would
have an adjusted target height higher than predicted. At
the extreme low end of parental heights (e.g., 15cm below
the mean), this correction would add about 4cm to the
unadjusted target height. Height and adjusted target height
SDSwerecalculatedusingreferencenormsandmethodology
established by Tanner [6].
Lastly, a corrected height SDS was computed based
on an individual’s adjusted target height SDS and current
height SDS. The corrected height SDS is the current height
SDS minus the adjusted target height SDS and provides an
estimate of each patient’s height deﬁcit within the context of
his or her individual genetic growth potential. Severe short
stature was deﬁned as a height more than 3SDs below the
mean or 1.5SDs below the adjusted target height per Growth
Hormone Research Society (GRS) guidelines for immediate
investigation [7]. Moderate short stature was deﬁned as a
height above −3SDs or less than 1.5SDs below the adjusted
target height.
2.1. Data Analysis. Descriptive statistics are presented as
frequency and percentage or mean and standard deviation.
All eligible patients are summarized. For selected variables,
an additional summary by severity of short stature was
generated. Comparisons of auxologic variables by severity
of short stature were performed using Student’s t-tests.
Comparisons of frequency of lab tests by severity of short
stature were made using Fisher’s exact tests. Chi-squared
tests were used for comparisons of return rates by severity
of short stature. To mitigate the eﬀects of the large sample
size, an alpha level of 0.001 was chosen to deﬁne statistical
signiﬁcance.
3. Results
3.1. Demographics. A total of 21,548 untreated short-
statured patients were eligible for enrollment from 237
participating institutions and clinical practices over the 44-
month enrollment period. The mean patient age (±SD) at
enrollment was 8.6±4.6 years (69% male). The majority
of patients were prepubertal (73%) and white (76% versus
75.1% of population). The referral rate of African-American
(5% versus 12.3% of population) and Hispanic (10% versus
12.5% of population) patients demonstrated an underrep-
resentation according to data within the 2000US Census
Bureau [8].International Journal of Pediatric Endocrinology 3
The mean (±SD) height SDS of referred children was
−2.1 (±0.9). The mean adjusted target height SDS was −0.3
(±0.7), and the mean corrected height SDS was −1.8 (±1.0).
The height SDS was below −3SDs in 13%, between −3a n d
−2 in 44%, and −2 or above in 44%. In 56% of patients,
heights were more than 1.5SDs below the adjusted target
height. The initial bone age was available in 13,810 patients,
and a mean delay of 1.5 years was calculated.
Overall, 59% of our population met at least one of
the GRS criteria for short stature [7] requiring immediate
investigation (i.e., height below −3.0SDs and/or corrected
height SDS more than 1.5SDs below adjusted target height)
(Table 1). Compared with moderately short patients, the
severely short patients were slightly older, had a greater bone
age delay, and had a higher target height (Table 1).
Turner syndrome was present or diagnosed in 3.4% of
female subjects (n = 226). Patients with Turner syndrome
with moderate short stature, as compared with those with
severe short stature, were younger, had less bone age delay,
and had shorter parents (Table 2).
3.2. Screening Tests. Table 3 shows the screening tests
reported during the short stature evaluation and the relative
frequency of use for moderate and severe short stature.
T h e s et e s t sm a yh a v eb e e np e r f o r m e dp r i o rt or e f e r r a lo ra t
any time during the pediatric endocrinologist’s assessment.
Bone age and thyroid tests were the most common screening
procedures. IGF-1 was reported in 42% of severely short
patients, in 31% of moderately short patients, and at a
similar frequency as the chemistry panel for all patients.
Celiac screening was rarely performed. All tests except liver
function tests were obtained with a higher frequency in
the severely short patients. Although female patients had
signiﬁcantly more karyotypes performed than male patients
(P<. 001 for total group comparison, male data not shown),
karyotypes were recorded for only one in ﬁve severely
short females. As reference, the survey results (percentage of
physicians reporting test use during screening) are included.
No screening test was recorded at the frequency stated in the
survey regardless of the degree of short stature in the patient.
3.3. Return Rate. Although all patients were scheduled for
at least one follow-up visit, 38% of the patients studied
did not return after the initial visit and only about 35%
had more than two visits (Figure 1). Among those who
failed to return, there was a slight excess of females, patients
with moderate short stature, pubertal patients, and African-
Americans (Table 4). Auxologic characteristics for patients
who returned and those who did not are presented in
(Table5).Themostcommontestsorderedatfollow-upvisits
includedboneage(34%),thyroidpanel(22%),IGF-1(22%),
and GH stimulation (21%).
4. Discussion
We reviewed data for over 21,000 patients from 237 pediatric
endocrine oﬃces who were enrolled in NCGS Substudy 8















Figure 1: Percentage of patients who had at least “n” visits with a
pediatric endocrinologist. For example, about 60% of all patients
had at least 1 follow-up visit (i.e., visit 2).
knowledge, this is the largest published collection of practice
data for this type of patients. The size and breadth of this
study should provide a good representation of pediatric
endocrine practice in the United States. Two ﬁndings stand
out: the low rate of initial laboratory testing and the low rate
of return for scheduled follow-up.
When the reported approach to a short-statured patient
(from data obtained in the 1995 survey) and the recorded
evaluation in the oﬃce setting (data obtained from Substudy
8) were compared, large diﬀerences between theory and
practice were discovered. For example, IGF-1, which may
reﬂect GH adequacy, was obtained in less than 40% of
these short children at the initial visit but was reported as
a routine test “always done” in 64% of patients in the survey.
Furthermore, although the comparisons between severely
and moderately short patients in (Table 3) are statistically
signiﬁcant, none of the diﬀerences in test rates appear
to be clinically meaningful; test rates were low essentially
regardless of stature.
The reason for the low test rate remains unclear,
especially when 59% of the referred patients met the GRS
criteria requiring “immediate investigation.” There are some
evidence-based guidelines for initial laboratory screening of
this population. There may be merit in celiac screening and
for karyotyping of short females [9], but there are few data
for other tests or for the prevalence of other conditions in
short children. Lack of such information limits the scientiﬁc
validity of most screening guidelines and may be one reason
for such a wide variance in usage. Grote et al. have also
reported a low degree of laboratory screening in short
children referred to either a general clinic or a university
clinic [10] in the Netherlands, despite a well-publicized
consensus guideline in that country.
Accurate growth records might provide direction to the
evaluation [11–13] but may be available for only 50% of
referred children [2]. Forward monitoring may also help
direct subsequent laboratory investigation. However, it will
be diﬃcult to establish any meaningful growth pattern when4 International Journal of Pediatric Endocrinology
Table 1: Characteristics of all subjects (including subjects with Turner syndrome) by degree of short stature.
Characteristic Moderate Severe Total
Age (y)
a 8.4 (±4.6; 8900) 8.8 (±4.6; 12,648) 8.6 (±4.6; 21,548)
Bone age delay (y)
a 1.1 (±1.3; 5250) 1.7 (±1.4; 8615) 1.5 (±1.4; 13,865)
Adjusted target height SDS
a −0.68 (±0.69; 7220) −0.14 (±0.63; 12,239) −0.34 (±0.7; 19,459)
Height SDS
b −1.6 (±0.77; 8900) −2.5 (±0.86; 12,648) −2.13 (±0.94; 21,548)
Corrected height SDS
b −0.9 (±0.63; 7220) −2.3 (±0.76; 12,239) −1.78 (±1.01; 19,459)
Values are mean (SD; n).
aP< . 001 moderate versus severe, Student’s t-test.
bVariables used to deﬁne severe or moderate short stature were not compared statistically.
Table 2: Characteristics of subjects with Turner syndrome by degree of short stature.
Characteristic Moderate Severe Total
Age (y)
a 4.5 (±3.7; 49) 8.4 (±4.7; 177) 7.6 (±4.8; 226)
Bone age delay (y)
a 0.3 (±0.8; 12) 1.4 (±1.6; 104) 1.3 (±1.5; 116)
Adjusted target height SDS
a −0.36 (±0.71; 31) 0.15 (±0.71; 166) 0.07 (±0.73; 197)
Height SDS
b −1.51 (±0.87; 49) −2.69 (±0.89; 177) −2.43 (±1.01; 226)
Corrected height SDS
b −0.82 (±0.77; 31) −2.76 (±0.83; 166) −2.46 (±1.09; 197)
Values are mean (SD; n).
aP< . 05 moderate versus severe, Student’s t test.
bVariables used to deﬁne severe or moderate short stature were not compared statistically.
Table 3: Percentage of children for whom screening tests were performed during evaluation.
Screening test 1995 Survey physicians
a
(reported) (n = 251)%
Moderate short
statureb (n = 8900)%
Severe short
stature(n = 12,648)%
Bone age 99 59 69
Thyroid panel 97 48 60
Chemistry panel 83 33 39
IGF-1 64 31 42
IGF BP-3 28 16 24
Hematocrit, ESR 79 28 32
Karyotype (female) 69 10 20
Urinalysis 79 12 15
HPG axis evaluation —7 1 0
Celiac screen 14 4 6
aReport stated that test was “always used” to screen a short child [3].
bAll variables reached a P<. 001 level of signiﬁcance comparing severe short stature to moderate short stature by Fishers exact test.
IGF-1:insulin-like growth factor 1; BP:binding protein; ESR:erythrocyte sedimentation rate; HPG:hypothalamic-pituitary-gonad.
Table 4: Percentage of patients who did not return after initial visit.
Status % Status %
All severe short 36 All moderate short 41
All male 37 All female 40
Male severe short 35 Male moderate short 40
Female severe short 38 Female moderate short 43
Male prepubertal 35 Male pubertal 41
Female prepubertal 37 Female pubertal 46
Turner severe short 38 Turner moderate short 43
White males 35 African-American males 44
White females 38 African-American females 46International Journal of Pediatric Endocrinology 5
Table 5: Characteristics of male and female subjects by return status.
Male Female
Characteristic Return No return Return No return
Age (y) 8.9 (4.6; 9329) 9.1 (4.8; 5482) 7.5 (4.3; 4046)
a 8.0 (4.5; 2691)
Bone age delay (y) 1.6 (1.3; 6283) 1.5 (1.3; 3445) 1.4 (1.4; 2503) 1.3 (1.5; 1634)
Target height SDS −0.32 (0.70; 8506) −0.35 (0.69; 4922) −0.36 (0.70; 3628) −0.38 (0.72; 2403)
Height SDS −2.11 (0.88; 9329)
a −2.04 (0.92; 5482) −2.27 (0.99; 4046)
a −2.19 (1.05; 2691)
Adjusted height SDS −1.78 (0.95; 8506)
a −1.68 (0.99; 4922) −1.91 (1.05; 3628)
a −1.80 (1.12; 2403)
Values are mean (SD, n).
aP< . 001, return status by gender.
almost 40% of patients will not return after the initial visit
and only 35% will have more than 2 visits regardless of the
degree of short stature [14]. Even for those with extended
follow-up, a change in height percentiles over time may not
be the most eﬀective auxologic screening tool. Distance from
adjusted target height (the adjusted height SDS) may be
a better tool for guiding laboratory testing [15], but was
apparently not often used in this study, as the testing rate was
low regardless of the adjusted target height.
The low return rate combined with the low rate of
laboratory screening at the initial visit results in an incom-
plete evaluation in the majority of the referred children.
The return rate was poor regardless of the severity of
short stature, the sex, or pubertal status, the adjusted target
height, or ethnicity. To validate the low return rates, charts
of all patients enrolled at one of the authors’ sites (the
Children’s Hospital of Wisconsin) were reviewed in detail.
The demographics of this patient subgroup were similar to
the national sample. Of the 422 patients enrolled at this site,
135 (32%) with unexplained short stature did not return
after the initial visit. Only one had been treated with growth
hormone (and transferred out of the study).
There are several possible interpretations for the poor
return rate. Families may not be as concerned about short
children as the physicians who refer them or the pediatric
endocrinologists who evaluate them. Some may have limited
access to specialist care for economic reasons, and some may
be inﬂuenced by the decision to simply monitor the child.
Some patients may have been placed on growth hormone,
though this is likely to account for only a small percentage of
the low return rate.
The minimal incidence of Turner syndrome in the NCGS
Substudy 8 population is 3.4% (226 of 6737 females), about
70-fold above that in the general population [16]. This
reﬂects the much higher yield when screening short females.
As expected, these girls fall farther behind their peers with
age. However, a karyotype was done in only 20% of referred
females, despite the common recommendation that short
females have such screening [17, 18], so we do not know the
true incidence of Turner syndrome in this population. The
study data do not allow us to determine whether children
with Turner syndrome were placed on rhGH treatment,
though such treatment may have contributed to the poor
recorded return rate.
When one GRS criterion (height SDS less than −3) was
applied to our group of patients, only 13% were classiﬁed as
severely short. Using another criterion (corrected height SDS
below −1.5) classiﬁed more than half (56%) of the children
as severely short. Thus, two GRS-suggested criteria lead to
quitediﬀerentclassiﬁcationsofthesamepopulation.Thereis
somesupportforpreferringthecorrectedheightSDScriteria
[15], at least for children above the age of 3 years. Further
study is needed to conﬁrm the best auxologic criteria by
which one may identify those children most likely to have
a pathology associated with their statural deﬁcit.
There are several potential limitations to the study.
Participating physicians were responsible for determining
which patients needed a follow-up visit and who would be
enrolled and for reporting the auxological and laboratory
data accurately. The potential for bias in these areas should
be somewhat balanced by the breadth of the referral sites and
the large number of subjects enrolled. Since the study was
closed to data entry about 8 years prior to publication, there
m a yh a v eb e e ns o m es u b s e q u e n tc h a n g ei np r a c t i c ep a t t e r n s .
In summary, we found that children referred to pediatric
endocrinologists for short stature evaluation have a low rate
of laboratory testing and a low rate of follow-up. Neither
ﬁnding is related to the severity of statural deﬁcit, whether
that deﬁcit is deﬁned relative to peers or parents.
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